Discovery of BR1733 for the treatment of SWI/SNF deficient or highly vascularized solid tumor
用户xqSbYLc7tnus
2小时前
30
10
已关闭
DOI:
文献链接:
其他信息:
X Wang, S Ma, M Xie, L Wang, Y Wang, S Zhang…
Cancer …, 2023
aacrjournals.org
… Activation mutation of EZH2, the catalytic subunit of the PRC2 complex, drives the progression
of tumors such as DLBCL… potent, selective, and orally bioavailable EED inhibitor BR1733. …

